

25th Oct 2017 | CannPal Animal Therapeutics Limited ACN: 612 791 518 | ASX:CP1

CannPal Receives Ethics Approval for the Commencement of Clinical Trial in Dogs

Key Highlights

- Ethics approval received for large pharmacokinetic and safety study in dogs
- CannPal's lead drug candidate, CPAT-01, is being developed as a pain medication for companion animals
- The trial subjects will be evaluated for safety, tolerability and clinical observations using both psychoactive (THC) and non-psychoactive (CBD) cannabis compounds
- Over 48 dogs will be evaluated over the course of three phases, with results from phases 1 and 2 anticipated in Q2 2018
- The study will be run by Invetus Limited, Australasia's largest veterinary research organization, in a state-of-the-art purpose built research facility in NSW

Animal health company **CannPal Animal Therapeutics Limited (ASX:CP1)** ("CannPal" or "the Company") is pleased to announce it has received ethics approval for the commencement of a large clinical study for the Company's lead drug candidate, CPAT-01, expected to begin Q1 2018 in Australia.

The approval is for phases 1 and 2 of CannPal's first clinical trial involving dogs. The study is being carried out in a state-of-the-art veterinary research facility in New South Wales (NSW) which was purpose-built to house over 100 dogs for companion animal research.

CannPal adviser Dr Ted Whitem, who has guided over 30 veterinary drugs through the approval process as the head of research and development at Jurox, helped design the study which is being run in collaboration with Invetus, Australasia's largest veterinary research organisation. Christine Budd, a veterinary surgeon at Invetus with over 24 years of experience, will run the study as principal investigator.

The trial is a comprehensive three-phase pharmacokinetic and safety study involving over 48 dogs that will assess the tolerability, safety profile and observational effects of tetrahydrocannabinol (THC), cannabidiol (CBD) and the Company's proprietary cannabinoid formulation at different dosages. The ethics approval follows the pre-clinical research conducted by the Company leading up to its Initial Public Offering (IPO). The study is expected to begin in Q1 2018 with results from phases 1 and 2 anticipated in Q2 2018.

CPAT-01 is being developed as a pain treatment for companion animals to provide a safe and efficacious alternative to Non-Steroidal Anti-Inflammatories (NSAID) which have a global market value of over US\$1.4billion.

The ethics approval will allow CannPal to progress through the steps required to import, possess and supply cannabis oils for research and commence further trials in accordance with the Company's schedule for early 2018.



It also confirms that the trial is ethically acceptable and follows the guidelines set out by the APVMA (Australian Pesticides and Veterinary Medicine Authority) for research in animals.

CannPal's Founder and Managing Director Layton Mills

We are delighted to have received the ethics approval for the commencement of our clinical study. It's an exciting milestone that signifies the beginning of the clinical phase of CannPal's development plans for CPAT-01. The study will provide our researchers with invaluable insight into the pharmacokinetics and safety profiles of cannabinoids in dogs, which is a crucial step in the drug development process.

About CannPal Animal Therapeutics

CannPal Animal Therapeutics Limited (ASX: CP1) is a pharmaceutical-focused animal health Company researching the benefits of medical cannabis for companion animals.

CannPal is researching and developing medicines derived from cannabinoids to provide veterinarians with clinically validated and standardised therapeutics to treat animals in a safe and ethical way.

CannPal has identified a significant opportunity to benefit from the rapidly growing medical cannabis and health markets by developing innovative therapeutics derived from the cannabis plant. The Company is working closely with regulatory authorities and veterinary research organisations conducting clinical trials to commercialise therapeutic products that will meet regulatory approval and support the health and well-being of companion animals.

To learn more please visit: www.cannpal.com

Baden Bowen *Company Secretary, CannPal Animal Therapeutics*

END

For further information, please contact:

CannPal
Layton Mills
Founder and Managing Director
M: +61 431 302 667
E: layton@cannpal.com

Media enquiries
Julia Maguire
The Capital Network
M: +61 419 815 386
E: julia@thecapitalnetwork.com.au

 [@CannPalAT](https://twitter.com/CannPalAT)

 facebook.com/CannPal